title: Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.
abstract: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT).
  
  
  
  One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated.
  
  
  
  The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS.
  
  
  
  Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.
authors.affiliation: From the *Division of Hematology, Oncology, and Bone and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA; †Banner MD Anderson Cancer Center, Gilbert, AZ; ‡Medical Associates Clinic, Dubuque; and §Department of Biostatistics, College of Public Health, University of Iowa; ∥Department of Radiology, University of Iowa Hospitals and Clinics; ¶Iowa City Veterans Administration Medical Center; #Division of Endocrinology and Metabolism and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics; and **Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA; ††Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; ‡‡Division of Surgical Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA; and §§Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN.
authors.forename: Nancy
authors.initials: N
authors.lastname: Sharma
authors.forename: Boris G
authors.initials: BG
authors.lastname: Naraev
authors.forename: Eric G
authors.initials: EG
authors.lastname: Engelman
authors.forename: M Bridget
authors.initials: MB
authors.lastname: Zimmerman
authors.forename: David L
authors.initials: DL
authors.lastname: Bushnell
authors.forename: Thomas M
authors.initials: TM
authors.lastname: OʼDorisio
authors.forename: M Sue
authors.initials: MS
authors.lastname: OʼDorisio
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Menda
authors.forename: Jan
authors.initials: J
authors.lastname: Müller-Brand
authors.forename: James R
authors.initials: JR
authors.lastname: Howe
authors.forename: Thorvardur R
authors.initials: TR
authors.lastname: Halfdanarson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007484:Iowa; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D015282:Octreotide